ERDRP-0519

ERDRP-0519

Legal status
Legal status	US: Investigational New Drug
Identifiers
IUPAC name 2-methyl-N-[4-[(2S)-2-(2-morpholin-4-ylethyl)piperidin-1-yl]sulfonylphenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide
CAS Number	1374006-96-8  Y
PubChem CID	57521469
ChemSpider	28514843
UNII	V5S4Z5Q9VU
Chemical and physical data
Formula	C23H30F3N5O4S
Molar mass	529.58 g·mol−1
3D model (JSmol)	Interactive image
SMILES Cn1c(cc(n1)C(F)(F)F)C(=O)Nc2ccc(cc2)S(=O)(=O)N3CCCC[C@H]3CCN4CCOCC4
InChI InChI=1S/C23H30F3N5O4S/c1-29-20(16-21(28-29)23(24,25)26)22(32)27-17-5-7-19(8-6-17)36(33,34)31-10-3-2-4-18(31)9-11-30-12-14-35-15-13-30/h5-8,16,18H,2-4,9-15H2,1H3,(H,27,32)/t18-/m0/s1 Key:JVZHTUQIMBYDSX-SFHVURJKSA-N

ERDRP-0519 is an antiviral drug which is the first drug specifically developed to target the measles morbillivirus. It acts as an inhibitor of the viral enzyme RNA polymerase which is essential for viral replication, and in animal studies showed good oral bioavailability and protected ferrets from otherwise lethal doses of a morbillivirus when administered up to three days after infection. ^{[1] [2]}

History

The research was done at Georgia State University and the Paul Ehrlich Institute. ^[3]

See also

• Favipiravir
• JK-05
• Sofosbuvir

References

1. White LK, Yoon JJ, Lee JK, Sun A, Du Y, Fu H, et al. (July 2007). "Nonnucleoside inhibitor of measles virus RNA-dependent RNA polymerase complex activity". Antimicrobial Agents and Chemotherapy. 51 (7): 2293–2303. doi:10.1128/AAC.00289-07. PMC   1913224 . PMID   17470652.
2. Krumm SA, Yan D, Hovingh ES, Evers TJ, Enkirch T, Reddy GP, et al. (April 2014). "An Orally Available, Small-Molecule Polymerase Inhibitor Shows Efficacy Against a Lethal Morbillivirus Infection in a Large Animal Model". Science Translational Medicine. 6 (232): 232ra52. doi:10.1126/scitranslmed.3008517. PMC   4080709 . PMID   24739760.
3. Grush L (2015-03-24). "New oral drug can stop measles infection before symptoms begin". Fox News. Retrieved 2020-11-18.